本公司及其董事、监事、高级管理人员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 仁和药业股份有限公司第十届董事会第二次会议通知于 2025 年 8 月 11 日以 直接送达、电子邮件等方式发出，会议于 2025 年 8 月 22 日以现场与通讯结合方 式在南昌元创国际 18 层公司会议室召开。会议应到董事 9 人，实到董事 9 人。 董事长杨潇先生主持本次会议，会议符合《公司法》和《公司章程》的有关规定。 经与会董事认真审议，会议审议通过了如下议案： 证券代码：000650 证券简称：仁和药业 公告编号：2024-032 仁和药业股份有限公司 第十届董事会第二次会议决议公告 一、审议通过了《公司 2025 年半年度报告全文及摘要的议案》 经审议，董事会认为：公司《2025 年半年度报告全文》及《2025 年半年度 报告摘要》的内容真实、准确、完整地反映了公司的实际情况，不存在任何虚假 记载、误导性陈述或者重大遗漏；报告的编制和审核程序符合法律、行政法规的 要求，符合中国证监会和深交所的相关规定。 具体内容详见巨潮资讯网（http://www.cninfo.com.cn）刊登的《公 ...

仁和药业股份有限公司 2025 年半年度报告全文 仁和药业股份有限公司 2025 年半年度报告 2025-035 【2025 年 8 月】 1 仁和药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人杨潇、主管会计工作负责人彭秋林及会计机构负责人(会计主 管人员)朱凌云声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 《证券日报》《证券时报》《中国证券报》和巨潮资讯网 www.cninfo.com.cn 为本公司 2025 年半年度选定的信息披露媒体，本公司所 有信息均以在上述选定媒体刊登的信息为准。同时，报告期内，不存在对公 司生产经营产生实质性影响的特别重大风险。公司已在本报告中阐述公司在 生产经营过程中可能面临的各种风险，请查阅第三节管理层讨论及分析中 "公司面临的风险和应对措施",敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | ...

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

证券之星消息，8月22日中药板块较上一交易日上涨0.08%，太龙药业领涨。当日上证指数报收于 3825.76，上涨1.45%。深证成指报收于12166.06，上涨2.07%。中药板块个股涨跌见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000650 | 仁和药业 | 6.65 | -5.27% | 316.23万 | 21.24亿 | | 603998 | 方盛制药 | 12.16 | -4.03% | 55.75万 | 6.85亿 | | 833266 | 生物谷 | 11.40 | -3.06% | 5.58万 | 6366.50万 | | 300147 | ST香雪 | 10.74 | -2.98% | 40.54万 | 4.43亿 | | 000590 | 启迪药业 | 12.44 | -2.43% | 11.51万 | 1.43亿 | | 002424 ...

Economic Information - According to the China Index Academy, as of August 2025, the debt restructuring and reorganization of 20 distressed real estate companies will exceed 12,000 billion RMB, significantly impacting the real estate sector [2] - As of August 13, the national pig price was 14.25 RMB/kg, down 1.32% from August 6, with the pig-to-grain price ratio at 5.94, a decrease of 1.33% [2] Company Alerts - Jishi Media reported a net loss of 232 million RMB in the first half of the year [5] - Dameng Data had two directors investigated within three days [5] - Kanglong Chemical's net profit for the first half of the year was 701 million RMB, a decrease of 37% year-on-year [5] - Yunmei Energy reported a net loss of 163 million RMB in the first half of the year [5] - Zhuosheng Microelectronics experienced a net loss of 147 million RMB in the first half, marking a transition from profit to loss [5] - Penghui Energy reported a net loss of 88.23 million RMB in the first half, also transitioning from profit to loss [5] - Aoxin Security reported a net loss of 356 million RMB in the first half [5] - Anyuan Coal Industry reported a net loss of 290 million RMB in the first half [5] - Guangsheng Tang reported a net loss of 66.6881 million RMB in the first half [5] - Yiyuan Lithium Energy's net profit decreased by 24.9% year-on-year in the first half [5] - Zhongtian Rocket's net profit decreased by 80.74% year-on-year in the first half [5] - Jianjie Industrial reported a net profit of 48.8658 million RMB in the first half, down 44.90% year-on-year [5] - Nanjing Chemical Fiber reported a net loss of 88.9317 million RMB in the first half [5] - Sanwei Xinan reported a net loss of 29.3858 million RMB in the first half [5] - Taiping Bird reported a net profit of 77.7116 million RMB in the first half, down 54.61% year-on-year [5] - Aerospace Power reported a net loss of 73.1243 million RMB in the first half [5] - Renhe Pharmaceutical's subsidiary product ULook brain-machine interaction smart glasses has not generated sales revenue [5] - Rhein Biotech experienced a safety incident resulting in one death and three serious injuries [5] - Guangfeng Technology's arbitration ruling is expected to reduce the consolidated profit for 2025 by approximately 91 million RMB [5] Overseas Alerts - The three major U.S. stock indices experienced slight declines, with the S&P 500 down 0.4%, marking its fifth consecutive day of decline [4] - The U.S. Department of Justice plans to investigate Federal Reserve Governor Lisa Cook and has urged Fed Chairman Powell to dismiss her [4] - According to the International Copper Study Group, a surplus of 36,000 tons in the global refined copper market is expected by June 2025 [4]

Market Overview - Kosun Technology (603626) achieved a five-day consecutive rise, while Garden Holdings (605303) saw a four-day rise, and Yuyin Co. (002177) and Shimao Energy (605028) experienced three-day rises [1] - The Shanghai Composite Index reached a high of 3787.98 points before retreating, with the market showing mixed performance across the three major indices [1] - The total trading volume in the Shanghai and Shenzhen markets was 2.42 trillion yuan, an increase of 158 billion yuan compared to the previous trading day, marking the seventh consecutive day of trading volume exceeding 2 trillion yuan [1] - Over 3000 stocks in the market declined, with sectors such as oil and gas, digital currency, beauty care, and banking showing the most significant gains [1] Company Highlights - Wantai Biological Pharmacy (603392) announced that its nine-valent HPV vaccine has received the batch release certificate, allowing it to enter the market and enhance the company's product lineup and revenue growth potential [2] - SANY Heavy Industry (600031) reported a 46% year-on-year increase in net profit for the first half of 2025, with total revenue reaching 44.534 billion yuan, a 14.96% increase [3] - The company plans to distribute a cash dividend of 3.10 yuan per 10 shares to shareholders [3] - SANY's overseas sales revenue was 26.302 billion yuan, accounting for 60.26% of its main business revenue, reflecting an 11.72% year-on-year growth [3] - Renhe Pharmaceutical (000650) clarified that its ULook brain-machine interaction smart glasses have not yet generated sales revenue, as the product is still in the testing phase and does not significantly impact the company's current performance [4]

Core Viewpoint - Renhe Pharmaceutical announced that its stock price experienced an abnormal fluctuation, with a cumulative increase of over 20.42% over two consecutive trading days on August 20 and 21, 2025 [1] Group 1: Company Operations - The company confirmed that its recent operational conditions are normal and that there have been no significant changes in the internal and external operating environment [1] - There are no undisclosed significant matters involving the company, its controlling shareholders, or actual controllers [1] Group 2: Product Development - The company's subsidiary has developed a brain-machine interaction smart glasses product named ULook, which currently only has sample production and has not yet generated sales revenue [1] - The ULook product's current status does not have a significant impact on the company's overall performance [1]

Buyback and Shareholder Actions - Sinopec plans to repurchase A-shares with a total fund of no less than RMB 5 billion and no more than RMB 10 billion, potentially reducing its registered capital [1] - Hengbang Mining intends to reduce its stake in the Hong Kong-listed company, WanGuo Gold, by up to 40 million shares, representing approximately 3.69% of WanGuo's total share capital [5] Product Approvals and Market Launches - Wantai Biological's nine-valent HPV vaccine has received the batch release certificate, marking its official market launch and enhancing the company's product lineup [1] - Changchun High-tech's subsidiary has received acceptance for the clinical trial application of GenSci143, a dual-specific antibody drug, which may provide new treatment options for certain tumors [7] Financial Performance - Hongxin Electronics reported a 15.01% increase in revenue to RMB 3.494 billion and a 9.85% rise in net profit to RMB 53.99 million for the first half of 2025 [2] - Sanwei Xinan experienced a net loss of RMB 29.39 million in the first half of 2025, despite a 15.19% increase in revenue to RMB 195 million [3] Corporate Developments - TianTan Bio received a commitment from its controlling shareholder to resolve new competition issues arising from a recent acquisition [4] - Feilu Co. announced a potential change in control, leading to a temporary suspension of its stock trading [8] Investment and Expansion - Jinbei Electric's subsidiary has signed a purchase agreement for a factory in Europe, marking significant progress in establishing its European production base [1] - Shengshi Technology plans to establish a wholly-owned subsidiary to integrate AI and humanoid robot technology with innovative toy products, investing RMB 10 million [6]

Company Announcements - Dameng Data's board member and senior vice president is under investigation by the Hubei Provincial Supervisory Committee, but the company's operations remain normal [1] - Jishi Media reported a net loss of 232 million yuan in the first half of 2025, despite a revenue increase of 8.7% to 999.7 million yuan [2] - Wantai Biological's nine-valent HPV vaccine has received its first batch release certificate, marking its market entry and potential revenue growth [2] - Feilu Co., Ltd. is undergoing a change in control, leading to a suspension of its stock trading starting August 22 [2] Financial Performance - Sany Heavy Industry reported a 46% increase in net profit to 5.216 billion yuan in the first half of 2025, with a revenue of 44.534 billion yuan, up 14.96% [3] - EVE Energy's net profit decreased by 24.9% to 1.605 billion yuan, despite a revenue increase of 30.06% to 28.169 billion yuan [5] - GoerTek achieved a net profit increase of 15.65% to 1.42 billion yuan, with a revenue of 37.55 billion yuan, down 7.02% [6] Approvals and Projects - Changchun High-tech's subsidiary received acceptance for a clinical trial application for GenSci143, a dual-specificity antibody drug targeting B7-H3 and PSMA [7] - Zejing Pharmaceutical received approval for clinical trials of ZG005 and ZGGS18 in combination with a specific cancer drug [7] Financing and Capital Increase - Zhenghe Industrial plans to raise no more than 818 million yuan through a private placement for various projects and working capital [8] Shareholding Changes - Zhongyin Securities announced that Jiangxi Copper plans to reduce its stake by up to 3%, equating to 83.34 million shares [9] - Mengke Pharmaceutical's shareholders plan to transfer 22.946 million shares, representing 3.5% of the total share capital [15] Investments and Strategic Partnerships - Diou Home plans to establish a wholly-owned subsidiary with an investment of 500 million yuan to expand into the generative AI field [11] - Gree Green signed a strategic cooperation agreement with Weilan Lithium to develop ultra-high energy density battery materials and solid-state battery innovations [12]

Group 1: Financial Performance - Xinhua Department Store reported a net profit of 86.0081 million yuan for the first half of the year, a year-on-year decrease of 2.52% [1] - The company achieved operating revenue of 3.254 billion yuan, down 0.99% year-on-year [1] - Bilibili's Q2 revenue reached 7.34 billion yuan, a year-on-year increase of 20%, with adjusted net profit hitting 560 million yuan, also a record high [4] - Kuaishou's Q2 revenue was 35 billion yuan, up 13.1% year-on-year, with adjusted net profit of 5.6 billion yuan, marking a 20.1% increase [5] Group 2: Business Developments - Walmart raised its adjusted earnings per share forecast for FY2026 to between $2.52 and $2.62, with expected net sales growth of 3.75% to 4.75% for Q3 [2] - MINISO plans to expand its MINISO LAND stores overseas, leveraging its own IP alongside global IP collaborations [2] - Renhe Pharmaceutical's subsidiary ULook's brain-machine interaction smart glasses have not yet generated sales revenue, currently only in testing phases [3] Group 3: Market Trends and Innovations - Tencent Games showcased its full-chain AI creative solution VISVISE at the Gamescom 2025, covering various aspects of game production [3] - DeepSeek announced the release of DeepSeek-V3.1, designed for the next generation of domestic chips [7] - AliExpress launched a new marketing AI Agent to enhance product sales, significantly increasing the number of new products sold [8] Group 4: Investment and Financing - The autonomous vehicle company "White Rhino" completed nearly 500 million yuan in B+ round financing, focusing on product development and AI technology [8]